OBJECTIVE: To determine survival and mortality in a cohort of Spanish patients with scleroderma (systemic sclerosis, SSc) and to analyse whether survival is influenced by demographic, clinical or immunological variables or the extent of skin involvement. METHODS: The study included 79 patients diagnosed with SSc and taking part in a study to determine the extent of sclerosis, visceral involvement and immunological alterations. We studied the number of observed and expected deaths (the expected number being based on age- and sex-specific rates in the background population) and derived standardized mortality ratios with their 95% confidence intervals (CI). Cumulative survival after onset of the first symptom was estimated according to the Kaplan-Meier method. The Cox method was used to identify the prognostic factors. RESULTS: The mortality rate was 0.0249 deaths per person-year. Survival at 15 yr was 0.62 (95% CI 0.410-0.778). The standardized mortality ratio was 429.4% (95% CI 222-750). On crude analysis, lung involvement [forced vital capacity (FVC) <70%, pulmonary hypertension], SSc renal crisis, an active capillaroscopic pattern, pericardial effusion and age over 60 yr at diagnosis were associated with shorter survival. On multivariate analysis, only age at diagnosis over 60 yr, FVC <70% and SSc renal crisis were independent prognostic factors. CONCLUSIONS: The mortality rate associated with SSc showed a four-fold increase compared with the background population. Lung involvement and sclerodermal renal crisis were found to be independently associated with reduced survival.
OBJECTIVE: To determine survival and mortality in a cohort of Spanish patients with scleroderma (systemic sclerosis, SSc) and to analyse whether survival is influenced by demographic, clinical or immunological variables or the extent of skin involvement. METHODS: The study included 79 patients diagnosed with SSc and taking part in a study to determine the extent of sclerosis, visceral involvement and immunological alterations. We studied the number of observed and expected deaths (the expected number being based on age- and sex-specific rates in the background population) and derived standardized mortality ratios with their 95% confidence intervals (CI). Cumulative survival after onset of the first symptom was estimated according to the Kaplan-Meier method. The Cox method was used to identify the prognostic factors. RESULTS: The mortality rate was 0.0249 deaths per person-year. Survival at 15 yr was 0.62 (95% CI 0.410-0.778). The standardized mortality ratio was 429.4% (95% CI 222-750). On crude analysis, lung involvement [forced vital capacity (FVC) <70%, pulmonary hypertension], SSc renal crisis, an active capillaroscopic pattern, pericardial effusion and age over 60 yr at diagnosis were associated with shorter survival. On multivariate analysis, only age at diagnosis over 60 yr, FVC <70% and SSc renal crisis were independent prognostic factors. CONCLUSIONS: The mortality rate associated with SSc showed a four-fold increase compared with the background population. Lung involvement and sclerodermal renal crisis were found to be independently associated with reduced survival.
Authors: Robyn T Domsic; Tatiana Rodriguez-Reyna; Mary Lucas; Noreen Fertig; Thomas A Medsger Journal: Ann Rheum Dis Date: 2010-08-02 Impact factor: 19.103
Authors: Diogo S Domiciano; Eloisa Bonfá; Claudia T L Borges; Ronaldo A Kairalla; Vera L Capelozzi; Edwin Parra; Romy Beatriz Christmann Journal: Clin Rheumatol Date: 2010-06-11 Impact factor: 2.980
Authors: Jinhyun Kim; Sue Kyung Park; Ki Won Moon; Eun Young Lee; Yun Jong Lee; Yeong Wook Song; Eun Bong Lee Journal: Clin Rheumatol Date: 2009-12-03 Impact factor: 2.980
Authors: Shervin Assassi; Roozbeh Sharif; Robert E Lasky; Terry A McNearney; Rosa M Estrada-Y-Martin; Hilda Draeger; Deepthi K Nair; Marvin J Fritzler; John D Reveille; Frank C Arnett; Maureen D Mayes Journal: Arthritis Res Ther Date: 2010-09-02 Impact factor: 5.156
Authors: J J Swigris; X Zhou; F S Wamboldt; R du Bois; R Keith; A Fischer; G P Cosgrove; S K Frankel; D Curran-Everett; K K Brown Journal: Thorax Date: 2009-04-08 Impact factor: 9.139
Authors: Ch Kostopoulos; J Koutsikos; C Toubanakis; L A Moulopoulos; Ch Mamoulakis; E Gialafos; P P Sfikakis; Ch Zerva; M Mavrikakis; A Leondi Journal: Eur J Nucl Med Mol Imaging Date: 2007-10-06 Impact factor: 9.236
Authors: Eric Hachulla; Patrick Carpentier; Virginie Gressin; Elisabeth Diot; Yannick Allanore; Jean Sibilia; David Launay; Luc Mouthon; Patrick Jego; Jean Cabane; Pascal de Groote; Amélie Chabrol; Isabelle Lazareth; Loïc Guillevin; Pierre Clerson; Marc Humbert Journal: Rheumatology (Oxford) Date: 2009-01-27 Impact factor: 7.580